Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage
This trial is a phase IIa human clinical study, in which 60 patients with intracerebral hemorrhage (ICH) at basal ganglion or thalamus within 6 h after onset will be enrolled. Patients will be randomly assigned as treatment group or control group as 1:1 distribution. Early initiation of celecoxib within 6 h after ICH and treatment for 21 days will be performed. The safety will be evaluated by drug adverse effects. The efficacy will be assessed by hematoma expansion, brain edema, and 3-month modified Rankin scale.
• Acute ICH patients able to take the first dose within 6 hours after onset
• ICH location at basal ganglion or thalamus
• ICH volume \< 30 mL
• Normal renal function (creatinine \[Cr\] ≤ 1.3 mg/dL)
• No surgical indication
• Signed informed consent
• Consciousness clear or mild drowsiness
• Age 20-80 years old